We are excited to be hosting the Schrödinger APAC Webinar Series – over 6 weeks we will host 6 talks by expert panelists from Schrödinger and universities. In this series, we will explore how physics-based molecular modeling and state-of-the-art ML/AI tools are impacting the drug discovery pipeline, from virtual screening in hit discovery through property predictions in pharmaceutical formulation. By registering for the series you will have access to watch all 6 webinars.
Schrödinger is excited to be participating in the Lab of the Future Europe taking place on September 26th-27th in Amsterdam, Netherlands. Join us for a presentation by Noj Malcolm, Strategic Deployment Manager at Schrödinger, titled “Into the Clinic: Transforming the Drug Discovery Process with Digital Chemistry”.
In recent years, Schrödinger has led a deep transformation in the field of structure-based drug discovery, where free energy perturbation (FEP+) has emerged as an in silico assay with enormous and increasing impact on active drug discovery programs. However, the application of this technology is constrained by the availability of accurate structure for the relevant protein-ligand complex. And while advances in cryo-EM and AlphaFold are giving access to an ever increasing number of structures across diverse protein classes, significant refinement and accurate ligand placement is necessary to use these models for accurate FEP+ calculations.
Schrödinger is excited to be participating in the BioTechX Europe taking place on October 4th-6th at the Basel Congress Center, in Basel, Switzerland. Join us for a presentation by Erin Davis, Senior Vice President of Enterprise Informatics at Schrödinger, titled “Empowering a Predict-First Mindset in Drug Discovery using a Digital Chemistry Platform”.
Schrödinger is excited to be participating in the 11èmes Journées de la SFCi conference taking place on October 5th - 6th in Caen, France at the Espace Mancel inside Caen Castel. Join us for a presentation by Dr. Zeineb Si Chaib, Senior Scientist in Application science at Schrödinger, titled “Expanding the Domain of Applicability of Structure-Based Drug Design with IFD-MD”.
Schrödinger is excited to be participating in the Chinese Medicinal Chemistry Symposium and CPA-EFMC Symposium taking place on October 7th-10th in Chongqing, China. Join us for a presentation by Jianxin Duan, Fellow in Applications Science at Schrödinger, titled “In Silico Driven Discovery of Potent, Selective and Brain-penetrant DLK Inhibitors for the Treatment of Neurodegenerative Diseases”.
The job of drug hunters is becoming increasingly difficult as previously considered undruggable targets are becoming the norm. Advances in molecular modeling and machine learning are changing the way chemists and biologists approach their drug discovery challenges – in modalities ranging from small molecules to biologics, and from hit discovery through lead optimization.
Schrödinger is excited to be participating in the Bio-Europe conference taking place on November 6th-8th in Munich, Germany. Visit us our booth to gain hands-on experience with Schrödinger software and meet our expert computational scientists.